Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 278,904
  • Shares Outstanding, K 8,101
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,460 K
  • 60-Month Beta 2.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.25
Trade ANVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.08 +10.82%
on 07/30/21
132.00 -72.23%
on 07/23/21
-60.34 (-62.21%)
since 07/02/21
3-Month
21.25 +72.52%
on 05/06/21
132.00 -72.23%
on 07/23/21
+15.11 (+70.12%)
since 05/04/21
52-Week
4.14 +785.51%
on 11/02/20
132.00 -72.23%
on 07/23/21
+30.86 (+532.07%)
since 08/04/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS). Such investors are advised to contact at or 888-476-6529,...

ANVS : 36.66 (-2.00%)
Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Annovis Bio, Inc. (ANVS) Common Stock

New York, New York--(Newsfile Corp. - August 2, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Annovis Bio, Inc. common stock (NYSE American: ANVS)....

ANVS : 36.66 (-2.00%)
Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease

ANVS : 36.66 (-2.00%)
Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm

/PRNewswire/ -- Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ("Annovis"...

ANVS : 36.66 (-2.00%)
Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference

Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD),...

ANVS : 36.66 (-2.00%)
Annovis Bio to Present New Data at 2021 Alzheimer's Association International Conference

Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD),...

ANVS : 36.66 (-2.00%)
Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study

Berwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD),...

ANVS : 36.66 (-2.00%)
Thinking about trading options or stock in Celldex Therapeutics, Tesla, Prothena Corp, Microsoft, or Annovis Bio?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLDX, TSLA, PRTA, MSFT, and ANVS.

CLDX : 44.84 (-0.11%)
MSFT : 286.51 (-0.21%)
PRTA : 54.70 (+1.11%)
TSLA : 710.92 (+0.17%)
ANVS : 36.66 (-2.00%)
Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials

Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD),...

ANVS : 36.66 (-2.00%)
Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO

Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company that addresses Alzheimer's disease...

ANVS : 36.66 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 41.61
2nd Resistance Point 40.52
1st Resistance Point 38.59
Last Price 36.66
1st Support Level 35.57
2nd Support Level 34.48
3rd Support Level 32.55

See More

52-Week High 132.00
Fibonacci 61.8% 83.16
Fibonacci 50% 68.07
Fibonacci 38.2% 52.98
Last Price 36.66
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar